Literature DB >> 8549112

Studies on the suitability of alpha-hybrid interferon application in cattle.

O C Straub1.   

Abstract

Twelve cattle with body wts ranging from 100 to 250 kg were treated using various doses and routes for four days with an E. coli derived alpha-hybrid interferon. The lowest parenteral doses (10(4) units per kg body wt) and the orally administered interferon did not lead to any disturbances, whereas the higher dosages led to marked changes in body temperature, pulse and respiration rates. Animals with the highest dose (10(8) units per kg body wt) became extremely distressed. The blood picture showed distinct changes, with very low leukocyte counts during treatment, which took weeks to recover. It is suggested that the dosages that did not lead to clinical symptoms are best suited for prophylactic or therapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8549112      PMCID: PMC7134301          DOI: 10.1016/0147-9571(95)00013-x

Source DB:  PubMed          Journal:  Comp Immunol Microbiol Infect Dis        ISSN: 0147-9571            Impact factor:   2.268


  15 in total

1.  [Local interferon production in cattle after intranasal infection with avirulent IBR/IPV virus and its effect on a subsequent infection with foot-and-mouth disease virus].

Authors:  C Straub; R Ahl
Journal:  Zentralbl Veterinarmed B       Date:  1976-06

2.  [Initial experiences in the treatment of virus-induced diarrheas in calves with interferon produced by genetic engineering].

Authors:  W Hofmann; K Danner; K Seeger
Journal:  Dtsch Tierarztl Wochenschr       Date:  1985-07-24

3.  Protection of cattle from infection with vaccinia virus by bovine interferon alpha C.

Authors:  A Schwers; J E Severin; M Bublot; M Maenhoudt; P P Pastoret; C Vanden Broecke; P Zilimwabagabo; B Velan; S Cohen; A Shafferman
Journal:  Vet Rec       Date:  1989-07-01       Impact factor: 2.695

4.  [Local interferon-production in the respiratory- and genital tract following infection with rhinotracheitis (IBR) and herpes exanthema (IPV) virus].

Authors:  R Ahl; O C Straub
Journal:  Dtsch Tierarztl Wochenschr       Date:  1971-12-15

5.  Susceptibility of bovine rotavirus to interferon. Brief report.

Authors:  L Dagenais; P P Pastoret; C Van den Broecke; J Werenne
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

6.  Interferon activity in rotavirus infected newborn calves.

Authors:  C La Bonnardière; J Cohen; M Contrepois
Journal:  Ann Rech Vet       Date:  1981

7.  Effect of recombinant DNA-derived bovine and human interferons on replication of bovine herpesvirus-1, parainfluenza-3, and respiratory syncytial viruses.

Authors:  R W Fulton; L J Burge; J S McCraken
Journal:  Am J Vet Res       Date:  1986-04       Impact factor: 1.156

8.  Studies of the effect of recombinant human-alpha 1 interferon on experimental parainfluenza type 3 virus infections of the respiratory tract of calves.

Authors:  D G Bryson; M S McNulty; R T Evans; G Allan
Journal:  Vet Rec       Date:  1989-12-16       Impact factor: 2.695

9.  Levels of interferon in blood serum and toxicity studies of bacteria-derived bovine alpha I1 interferon in dairy calves.

Authors:  J H Gillespie; F W Scott; C M Geissinger; C W Czarniecki; V T Scialli
Journal:  J Clin Microbiol       Date:  1986-08       Impact factor: 5.948

10.  Effect of bovine alpha 1 interferon on bovine herpesvirus type 1-induced respiratory disease.

Authors:  L A Babiuk; H B Ohmann; G Gifford; C W Czarniecki; V T Scialli; E B Hamilton
Journal:  J Gen Virol       Date:  1985-11       Impact factor: 3.891

View more
  2 in total

Review 1.  Therapeutic and Prophylactic Use of Oral, Low-Dose IFNs in Species of Veterinary Interest: Back to the Future.

Authors:  Sara Frazzini; Federica Riva; Massimo Amadori
Journal:  Vet Sci       Date:  2021-06-11

2.  Low-dose interferon-α treatment improves survival and inflammatory responses in a mouse model of fulminant acute respiratory distress syndrome.

Authors:  Daisuke Kudo; Kazuko Uno; Tetsuji Aoyagi; Yukiko Akahori; Keiko Ishii; Emi Kanno; Ryoko Maruyama; Shigeki Kushimoto; Mitsuo Kaku; Kazuyoshi Kawakami
Journal:  Inflammation       Date:  2013-08       Impact factor: 4.092

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.